A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension - BaxHTN

Study identifier:D6970C00002

ClinicalTrials.gov identifier:NCT06034743

EudraCT identifier:N/A

CTIS identifier:EU CT 2023-505499-32

Recruiting

Official Title

A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension

Medical condition

Uncontrolled Hypertension

Phase

Phase 3

Healthy volunteers

No

Study drug

Baxdrostat, Placebo

Sex

All

Estimated Enrollment

720

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 22 Nov 2023
Estimated Primary Completion Date: 13 Oct 2025
Estimated Study Completion Date: 13 Oct 2025

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria